Skip to main content

Advertisement

Figure 2 | Molecular Cancer

Figure 2

From: Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia

Figure 2

Expression of miR-125b varied in different therapeutic response groups of pediatric APL. The qRT-PCR assay was repeated three times, and similar results were obtained. Representative results are shown as means ± standard deviation (M ± SD). Data presented are the fold changes of expression with respect to the bone marrow MNC from five healthy donors. (A) Expression level of miR-125b in different age groups of pediatric APL patients. (B) The expression levels of miR-125b in 33 pediatric APL patients before and after therapy are presented as fold changes of expression with respect to expression in bone marrow mononuclear cells (MNC) from healthy donors. MiR-125b levels for the same patient before and after therapy were paired. Data were sorted from lowest to highest levels of miR-125b in non-treated patients. (C) Expression level of miR-125b in pediatric APL patients before and after therapy. *p < 0.05, **p < 0.01.

Back to article page